Levetiracetam Hospira 100 mg / ml concentrate for solution for infusion – patient leaflet, side effects, dosage

1. What Levetiracetam Hospira is and what it is used for

Levetiracetam is an antiepileptic medicine (a medicine used to treat seizures in epilepsy). Levetiracetam Hospira is used:

• on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy,

  to treat a certain form of epilepsy. Epilepsy is a condition where the patients have repeated fits (seizures). Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation). Levetiracetam has been given to you by your doctor to reduce the number of fits.

• as an add-on to other antiepileptic medicines to treat:

  • partial onset seizures with or without generalisation in adults, adolescents and children from 4 years of age.
  • myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.
  • primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).

Levetiracetam Hospira concentrate for solution for infusion is an alternative for patients when administration of the antiepileptic levetiracetam medicine by mouth is temporarily not feasible.

2. What you need to know before you are given Levetiracetam Hospira

Do not use Levetiracetam Hospira

• If you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of

  this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor before you are given Levetiracetam Hospira

• If you suffer from kidney problems, follow your doctor’s instructions. He/she may decide if

  your dose should be adjusted.

• If you notice any slowdown in the growth or unexpected puberty development of your child,

  please contact your doctor.

• A small number of people being treated with anti-epileptics such as Levetiracetam Hospira

  have had thoughts of harming or killing themselves. If you have any symptoms of depression and/or suicidal ideation, please contact your doctor.

• If you have a family or medical history of irregular heart rhythm (visible on an

  electrocardiogram), or if you have a disease and/or take a treatment that make(s) you prone to heartbeat irregularities or salt imbalances.

Tell your doctor or pharmacist if any of the following side effects gets serious or last longer than a few days:

• Abnormal thoughts, feeling irritable or reacting more aggressively than usually, or if you or

  your family and friends notice important changes in mood or behaviour.

• Aggravation of epilepsy:

  Your seizures may rarely become worse or happen more often, mainly during the first

  month after the start of the treatment or increase of the dose.

  In a very rare form of early-onset epilepsy (epilepsy associated with SCN8A mutations) that causes multiple types of seizures and loss of skills you may notice that the seizures remain present or are becoming worse during your treatment.

  If you experience any of these new symptoms while taking Levetiracetam Hospira, see a doctor as soon as possible.

  Children and adolescents

  • Levetiracetam Hospira is not indicated in children and adolescents below 16 years on its own (monotherapy).

Other medicines and Levetiracetam Hospira

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.

Do not take macrogol (a drug used as laxative) for one hour before and one hour after taking levetiracetam as this may results in a reduction of its effect.

Pregnancy and breast-feeding

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Levetiracetam Hospira can be used during pregnancy, only if after careful assessment it is considered necessary by your doctor. You should not stop your treatment without discussing this with your doctor. A risk of birth defects for your unborn child cannot be completely excluded. Two studies do not suggest an increased risk of autism or intellectual disability in children born to mothers treated with levetiracetam during pregnancy. However, the available data regarding the impact of levetiracetam on neurodevelopment in children is limited. Breast-feeding is not recommended during treatment.

Driving and using machines

Levetiracetam Hospira may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy. This is more likely at the beginning of treatment or after an increase in the dose. You should not drive or use machines until it is established that your ability to perform such activities is not affected.

Levetiracetam Hospira contains sodium

One maximum single dose of Levetiracetam Hospira concentrate contains 2.5 mmol (or 57 mg) of sodium (0.8 mmol (or 19 mg) of sodium per vial). This is equivalent to 2.85% of the recommended maximum daily dietary intake of sodium for an adult. This should be taken into consideration if you are on a controlled sodium diet.

3. How Levetiracetam Hospira is given

A doctor or a nurse will administer you Levetiracetam Hospira as an intravenous infusion. Levetiracetam Hospira must be administered twice a day, once in the morning and once in the evening, at about the same time each day.

The intravenous formulation is an alternative to your oral administration. You can switch from the film-coated tablets or from the oral solution to the intravenous formulation or reverse directly without dose adaptation. Your total daily dose and frequency of administration remain identical. Adjunctive therapy and monotherapy (from 16 years of age)

Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more:

Recommended dose: between 1,000 mg and 3,000 mg each day.

When you first start taking Levetiracetam Hospira, your doctor will prescribe you a lower dose for 2 weeks before giving you the lowest daily dose.

Dose in children (4 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg:

Recommended dose: between 20 mg per kg bodyweight and 60 mg per kg bodyweight each day. Method and route of administration:

Levetiracetam Hospira is for intravenous use.

The recommended dose must be diluted in at least 100 ml of a compatible diluent and infused over 15-minutes.

For doctors and nurses, more detailed direction for the proper use of Levetiracetam Hospira is provided in section 6.

Duration of treatment:

• There is no experience with administration of intravenous levetiracetam for a longer period than 4 days.

If you stop using Levetiracetam Hospira:

If stopping treatment, as with other antiepileptic medicines, Levetiracetam Hospira should be discontinued gradually to avoid an increase of seizures. Should your doctor decide to stop your Levetiracetam Hospira treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam Hospira.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

The following information is intended for healthcare professionals only:

Directions for the proper use of Levetiracetam Hospira is provided in section 3.

One vial of Levetiracetam Hospira concentrate contains 500 mg levetiracetam (5 ml concentrate of 100 mg/ml). See Table 1 for the recommended preparation and administration of Levetiracetam Hospira concentrate to achieve a total daily dose of 500 mg, 1000 mg, 2000 mg, or 3000 mg in two divided doses.

Table 1. Preparation and administration of Levetiracetam Hospira concentrate

This medicinal product is for single use only, any unused solution should be discarded.

In use shelf life:

Chemical and physical in-use stability of the diluted product stored in PVC bags has been demonstrated for 24 hours at 30 °C and at 2-8 °C. From a microbiological point of view, unless the method of dilution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage time and conditions are the responsibility of the user.

Levetiracetam Hospira concentrate was found to be physically compatible and chemically stable when mixed with the following diluents:

• Sodium chloride 9 mg/ml (0.9%) solution for injection
• Lactated Ringer’s solution for injection

• Dextrose 50 mg/ml (5%) solution for injection

  2026-1000155-01

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Tell your doctor immediately, or go to your nearest emergency department, if you experience:

• weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of

  a serious allergic (anaphylactic) reaction

• swelling of the face, lips, tongue and throat (Quincke’s oedema)

• flu-like symptoms and a rash on the face followed by an extended rash with a high

  temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia), enlarged lymph nodes and the involvement of other body organs (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS])

• symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling

  in the legs, ankles or feet, as this may be a sign of sudden decrease of kidney function

• a skin rash which may form blisters and look like small targets (central dark spots

  surrounded by a paler area, with a dark ring around the edge) (erythema multiforme)

• a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes

  and genitals (Stevens-Johnson syndrome)

• a more severe form of rash causing skin peeling in more than 30% of the body surface

  (toxic epidermal necrolysis)

• signs of serious mental changes or if someone around you notices signs of confusion,

  somnolence (sleepiness), amnesia (loss of memory), memory impairment (forgetfulness), abnormal behaviour or other neurological signs including involuntary or uncontrolled movements. These could be symptoms of an encephalopathy.

The most frequently reported adverse reactions were nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness. At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common. These effects should however decrease over time.

Very common: may affect more than 1 in 10 people

• nasopharyngitis;
• somnolence (sleepiness), headache.

Common: may affect up to 1 in 10 people

• anorexia (loss of appetite);
• depression, hostility or aggression, anxiety, insomnia, nervousness or irritability;

• convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness),

  lethargy (lack of energy and enthusiasm), tremor (involuntary trembling);

• vertigo (sensation of rotation);
• cough;
• abdominal pain, diarrhoea, dyspepsia (indigestion), vomiting, nausea;
• rash;
• asthenia/fatigue (tiredness).

Uncommon: may affect up to 1 in 100 people

• decreased number of blood platelets, decreased number of white blood cells;
• weight decrease, weight increase;

• suicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination,

  anger, confusion, panic attack, emotional instability/mood swings, agitation;

• amnesia (loss of memory), memory impairment (forgetfulness), abnormal

  coordination/ataxia (impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration);

• diplopia (double vision), vision blurred;
• elevated/abnormal values in a liver function test;
• hair loss, eczema, pruritus;
• muscle weakness, myalgia (muscle pain);
• injury.

Rare: may affect up to 1 in 1,000 people

• infection;
• decreased number of all blood cell types;

• severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic

  reaction], Quincke’s oedema [swelling of the face, lips, tongue and throat]);

• decreased blood sodium concentration;

• suicide, personality disorders (behavioural problems), thinking abnormal (slow thinking,

  unable to concentrate);

• delirium;

• encephalopathy (see sub-section “Tell your doctor immediately” for a detailed description of

  symptoms);

• seizures may become worse or happen more often;

• uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling

  movements, hyperkinesia (hyperactivity);

• change of the heart rhythm (Electrocardiogram);
• pancreatitis;
• liver failure, hepatitis;
• sudden decrease in kidney function;

• skin rash, which may form blisters and looks like small targets (central dark spots

  surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes

  and genitals (Stevens-Johnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis);

  • rhabdomyolysis (breakdown of muscle tissue) and associated blood creatine phosphokinase increase. Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients;
  • limp or difficulty walking;
  • combination of fever, muscle stiffness, unstable blood pressure and heart rate, confusion, low level of consciousness (may be signs of a disorder called neuroleptic malignant syndrome). Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.

Very rare: may affect up to 1 in 10,000 people

• repeated unwanted thoughts or sensations or the urge to do something over and over again (Obsessive Compulsive Disorder).

Reporting of side effects

If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Levetiracetam Hospira

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the vial and carton box after EXP: The expiry date refers to the last day of the month.

This medicine does not require any special storage conditions.

6. Contents of the pack and other information

What Levetiracetam Hospira contains

• The active substance is called levetiracetam. Each ml contains 100 mg of levetiracetam.
• The other ingredients are: sodium acetate trihydrate, glacial acetic acid, sodium chloride, water for injections (see section 2 Levetiracetam Hospira contains sodium). What Levetiracetam Hospira looks like and contents of the pack

Levetiracetam Hospira concentrate for solution for infusion (sterile concentrate) is a clear, colourless solution.

Levetiracetam Hospira concentrate for solution for infusion is packed in a cardboard box containing 10 or 25 vials of 5 ml.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Pfizer Limited

Ramsgate Road

Sandwich

Kent

CT13 9NJ

United Kingdom

Manufacturer

Pfizer Service Company BV

Hermeslaan 11

1932 Zaventem

Belgium

For any information about this medicine, please contact:

Medical Information, Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS. Telephone 01304 616161

This leaflet was last revised in 02/2026.

Ref gxLT 21_0

2026-1000155-01